Takeda signs off on a $2B deal aimed at bypassing AAV roadblocks on the way to gene therapy 2.0
Takeda has taken another step down the road to building up its gene therapy platform.
The pharma giant announced Tuesday morning that it’s struck the latest in a series of deals with one of the upstarts in the field to explore new designs for delivery vehicles — looking to go far past the AAV prototypes that have driven the field so far.
The spotlight today falls on Code Biotherapeutics, a private startup run by ex-GSK BD chief Brian McVeigh.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.